We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




International Genomics Consortium Licenses Sapphire Biobanking Solution

By Labmedica staff writers
Posted on 21 Jul 2008
The International Genomics Consortium (IGC; Phoenix, AZ, USA) has licenced LabVantage Solutions, Inc (Bridgewater, NJ, USA) Sapphire BioBanking Solution. More...
The IGC chose Sapphire because of its product maturity, functionality, architecture, scalability, and flexibility.

A zero-footprint laboratory-information management suite, Sapphire is designed to manage an organization's critical laboratory information across worldwide operations, to optimize productivity, and more effectively share knowledge. The Sapphire BioBanking Solution ensures that standard procedures are used for all steps in the biorepository management process. Key processes supported include: informed consent, clinical data collection, sample collection, pathology review, biomolecule extractions, quality control, laboratory data collection, and biomolecule distribution.

A non-profit foundation, the IGC was established to expand upon the discoveries of the Human Genome Project and other systematic sequencing efforts by combining diagnostic technologies, genomic research, and bioinformatics, in the fight against cancer and other complex genetic diseases. The foundation has a number of functions including: standardization of the collection of properly consented tissues of interest, molecular characterization of these tissues, and standardization in the representation of these results. The IGC facilitates the transition of genomic discoveries to improve patient care and increase the speed in which new diagnostic, prognostic and predictive testing, and new drug and treatment regimens are developed.

The [U.S.] National Cancer Institute (NCI; Bethesda, MD, USA) and the [U.S.] National Human Genome Research Institute (NHGRI; Bethesda, MD) chose the IGC to lead the Human Cancer Biospecimen Core Resource (BCR) component of The Cancer Genome Atlas (TCGA) pilot project. The Sapphire BioBanking Solution will serve as a key informatics backbone supporting and maintaining the BCR.

"In order for the IGC to successfully implement the Human Cancer Biospecimen Core Resource we needed a biospecimen management solution that was functionally rich and capable of being implemented rapidly,” stated Troy Shelton, IGC project administrator for TCGA. "Among the software solutions we evaluated, LabVantage's Sapphire BioBanking Solution offered true out-of–the-box functionality and was by far the most well-established and premier solution used by peers in the industry.”


Related Links:
International Genomics Consortium
LabVantage Solutions
National Cancer Institute

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.